Category Archives: NMPA

China Seeks Input on Drug QTc Clinical Trial Guidelines

Leave a reply

Beijing, Aug 26, 2026 — China’s Center for Drug Evaluation (CDE) released draft technical guidelines for clinical research on drug concentration-QTc (C-QTc) relationships, opening a one-month public comment period to standardize cardiac safety assessments for innovative medicines.

Regulatory Snapshot

AttributeDetail
IssuerCenter for Drug Evaluation (CDE), National Medical Products Administration
DocumentDraft Technical Guidelines for Clinical Research of Drug Concentration QTc
ScopeC-QTc clinical studies and data analysis for cardiac safety evaluation
Target drugsInnovative medicines requiring cardiac safety profiling
Comment deadlineOne month from publication
ContactsWang Yuzhu (wangyzh@cde.org.cn); Ma Jingyi (majy@cde.org.cn)

Technical Context

The draft guidelines address concentration-QTc (C-QTc) modeling, a statistical approach used to evaluate whether a drug prolongs the corrected QT interval in an exposure-dependent manner. C-QTc analysis is increasingly favored as an alternative or complement to traditional thorough QT (TQT) studies under ICH E14 frameworks, allowing sponsors to integrate cardiac safety assessment into early-phase trials rather than conducting standalone studies.

Market Impact Analysis

The guideline marks a significant step in aligning China’s cardiac safety evaluation standards with international ICH E14 Q&A updates. For pharmaceutical developers, particularly those in oncology, central nervous system, and infectious disease pipelines where QT prolongation is a known class risk, the document provides a regulatory pathway to use C-QTc modeling as primary evidence for QT liability assessment. This could reduce clinical development timelines and costs by eliminating the need for separate TQT studies when robust exposure-response data is available.

The one-month comment window suggests CDE is moving quickly to finalize the guidance, reflecting urgency to keep pace with global regulatory convergence on cardiac safety methodologies. Domestic and multinational sponsors with pending new drug applications in China should review the draft closely, as the final version is likely to influence trial design for Phase I and Phase II studies currently in planning.

Forward-Looking Statement

Industry experts expect the finalized guidelines to be published by late 2026 or early 2027, following the comment period and potential revision. The adoption of C-QTc-centric guidance positions China to accept modeling-based cardiac safety waivers more routinely, potentially accelerating approvals for drugs in therapeutic areas where QT effects have historically triggered regulatory delays. Companies are advised to prepare C-QTc analysis capabilities—either internally or through specialized biostatistics contract research organizations—to align with the forthcoming mandatory standards.-China Health Reform Pulse

Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/77085aae69c2d59b829839cf7377f107

Policy Analysis & Guidance: China Halts Imports of Indonesian Eye Lens over Safety Risks

Leave a reply

China’s National Medical Products Administration (NMPA) announced on April 15 that it has suspended the import, sale, and use of artificial intraocular lenses produced by Indonesia’s Rohto Laboratories due to significant quality and safety concerns.

Policy Breakdown

  • Deficiencies Identified: During a remote inspection, the NMPA found severe flaws in the company’s quality management system, particularly in change control, product testing, and validation processes.
  • Regulatory Basis: The decision aligns with the Medical Device Supervision and Administration Regulations and the Medical Device Production Supervision and Administration Measures.
  • Public Safety Priority: The move underscores China’s commitment to safeguarding public health amid increasing medical device scrutiny.

Market Implications
The suspension could disrupt supply chains for intraocular lenses, a critical component in cataract surgeries. Analysts at China Healthcare Market Research suggest that domestic producers and alternative international suppliers may see short-term demand increases.

Industry Impact
This serves as a warning to medical device manufacturers on the importance of adhering to China’s stringent quality standards. Companies are urged to strengthen quality management systems to avoid similar restrictions.

Looking Ahead
Stakeholders should monitor whether the suspension prompts broader quality audits of imported medical devices. The incident highlights the need for robust compliance strategies in China’s medical device market.-China Health Reform Pulse

Policy Source: https://www.nmpa.gov.cn/ylqx/ylqxggtg/20250417153039134.html

Policy Analysis & Guidance: China’s Drug Regulatory Authority Strengthens Style Building

Leave a reply

The Communist Party of China (CPC) has intensified efforts to implement the spirit of the Central Eight Provisions, with the National Medical Products Administration (NMPA) hosting a dedicated study class from April 7 to 9. The initiative underscores the CPC’s commitment to enhancing work style and promoting high-quality development in the pharmaceutical sector.

Policy Breakdown

  • Learning Focus: The study class centered on President Xi Jinping’s discourse on work style and the details of the Central Eight Provisions, aiming to deepen understanding and practical application.
  • Leadership Emphasis: NMPA Party Group Secretary and Administrator Li Li stressed the critical role of work style in winning public support and ensuring success in undertakings, advocating the strictest standards and measures to address work style issues.
  • Implementation Strategy: Li Li highlighted the necessity of starting work style improvement from the leadership itself, setting examples and transmitting pressure at all levels. He also emphasized the ongoing nature of work style building, calling for relentless efforts to deepen it and unite the pharmaceutical regulatory cause with excellent work style.

Market Implications
The campaign is expected to enhance the credibility of drug regulatory authorities and boost public satisfaction. It also signals a push for more efficient and transparent regulatory processes, potentially accelerating the approval of innovative drugs and medical devices.

Industry Impact
Pharmaceutical companies can anticipate a more stable and supportive regulatory environment, encouraging greater investment in research and development. The focus on work style is also likely to reduce bureaucratic delays, streamlining market entry procedures.

Looking Ahead
As the style building campaign progresses, stakeholders should monitor how the NMPA’s enhanced work style translates into specific regulatory reforms and service improvements. The long-term goal is to create a more conducive environment for the pharmaceutical industry’s high-quality development.-China Health Reform Pulse

Policy Source: https://www.nmpa.gov.cn/yaowen/ypjgyw/hyxx/zhhyxx/20250410090048123.html